$VYNT News

Last published 3y ago

3y agoVYNTVyant Bio Announces Last Day of Trading on Nasdaq and Filing of Form 15 for Voluntary Nasdaq Delisting and SEC DeregistrationGlobeNewswireCHERRY HILL, N.J., May 12, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. ("Vyant Bio" or "Company") (NASDAQ:VYNT) is a biotechnology company that incorporates innovative biology and data science to improve drug discovery
3y agoVYNTVyant Bio Announces Filing of Form 25 for Voluntary Nasdaq Delisting and SEC DeregistrationGlobeNewswireCHERRY HILL, N.J., May 04, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. ("Vyant Bio" or "Company") (NASDAQ:VYNT) is a biotechnology company that incorporates innovative biology and data science to improve drug discovery
3y agoVYNTVyant Bio Announces Voluntary Nasdaq Delisting and SEC DeregistrationGlobeNewswireCHERRY HILL, N.J., April 24, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. ("Vyant Bio" or "Company") (NASDAQ:VYNT) is a biotechnology company that incorporates innovative biology and data science to improve drug discovery
3y agoVYNTVyant Bio Commences a Cash Preservation Plan Including a Reduction in ForceGlobeNewswireContinuing to Explore Strategic Alternatives CHERRY HILL, N.J., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. ("Vyant Bio" or "Company") (NASDAQ:VYNT) is an innovative biotechnology company reinventing drug
3y agoVYNTVyant Bio Engages LifeSci Capital to Explore Strategic AlternativesGlobeNewswireCHERRY HILL, N.J., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. ("Vyant Bio" or "Company") (NASDAQ:VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and
3y agoVYNTVyant Bio Presents Key Takeaways from Platform and Poster Presentations at Neuroscience 2022 Hosted by the Society for NeuroscienceGlobeNewswire"Targeting specific functional rescue in a Rett patient cortical organoid disease model" CHERRY HILL, N.J., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. ("Vyant Bio" or "Company") (NASDAQ:VYNT) is an innovative
3y agoVYNTVyant Bio Regains Compliance with Nasdaq Minimum Bid Price RequirementGlobeNewswireCHERRY HILL, N.J., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. ("Vyant Bio" or "Company") (NASDAQ:VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and
3y agoVYNTVyant Bio Reports Third Quarter 2022 Results and Provides Strategic and Business HighlightsGlobeNewswireQ3 2022 and Recent Scientific and Business Highlights Completed the sale of its vivoPharm subsidiary to Reaction Biology Corporation for $5.5 million in an upfront cash paymentDelivered platform and poster
4y agoVYNTVyant Bio Presents Key Takeaways from Platform and Poster Presentations at the 2022 CDKL5 Forum Hosted by the Loulou FoundationGlobeNewswireCHERRY HILL, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. ("Vyant Bio" or "Company") (NASDAQ:VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and
4y agoVYNTVyant Bio to Participate at Neuroscience 2022, the 52nd Annual Gathering of the Society for Neuroscience, on November 12-16GlobeNewswireCHERRY HILL, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. ("Vyant Bio" or "Company") (NASDAQ:VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and
4y agoVYNTVyant Bio Teams Up with the International Rett Syndrome Foundation to Host Local Viewing Party in Honor of the 3rd Annual 'Raise a Glass for Rett Gala'GlobeNewswireCharity Event to Drive Awareness and Support Rett Families Around the World CHERRY HILL, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. ("Vyant Bio" or "Company") (NASDAQ:VYNT) is an innovative
4y agoVYNTReaction Biology and Vyant Bio Announce Closing of Definitive Agreement to Acquire U.S. Operations of Vyant Bio, Inc. SubsidiaryGlobeNewswire~ Reaction Biology Acquires the Hershey, Pennsylvania-Based U.S. Operations of Vyant Bio Subsidiary vivoPharm PTY Ltd. ~ ~ Transaction Expands Reaction Biology's Capabilities to Provide Customers with Solutions in
4y agoVYNTVyant Bio Announces One-for-Five Reverse Stock SplitGlobeNewswireCHERRY HILL, N.J., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. ("Vyant Bio" or "Company") (NASDAQ:VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and
4y agoVYNTVyant Bio Announces Participation at the 2022 CDKL5 Forum Hosted by the Loulou Foundation on November 7-8, 2022GlobeNewswirePlatform and Poster Presentations on Vyant Bio's Human First Drug Discovery Platform and Progress on CDKL5 Deficiency Disorder (CDD) CHERRY HILL, N.J., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. ("Vyant Bio"
4y agoVYNTVyant Bio to Present at the LD Micro Main Event XV on Wednesday, October 26, 2022GlobeNewswire-To Discuss its Novel Drug Discovery Platform that is Accelerating the Process of Finding Cures for Neurogenerative Diseases CHERRY HILL, N.J., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. ("Vyant Bio" or
4y agoVYNTVyant Bio to Deliver a Live Presentation at the Skyline Signature Series™ on Thursday, September 8, 2022GlobeNewswire-Invites individual and institutional investors, as well as advisors and analysts, to attend this real-time, interactive presentation at the Skyline Signature Series™ CHERRY HILL, N.J., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. ("Vyant Bi
4y agoVYNTVyant Bio to Present at the H.C. Wainwright 24th Annual Global Investment ConferenceGlobeNewswireCHERRY HILL, N.J., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. ("Vyant Bio" or "Company") (NASDAQ:VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company'
4y agoVYNTVyant Bio Reports Second Quarter and First Half 2022 Results and Provides Strategic and Business HighlightsGlobeNewswireConference Call and Webcast Today at 4:30 pm ET Scientific and Business Highlights Based on preclinical efficacy data in our human Rett cortical organoid model, we are advancing VYNT0126 into clinical trials in Rett patients with encouragement
4y agoVYNTVyant Bio Announces Rescheduled Investor Conference Call and Webcast for the Second Quarter and First Half of 2022GlobeNewswireCHERRY HILL, N.J., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. ("Vyant Bio" or "Company") (NASDAQ:VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company'
4y agoVYNTVyant Bio Postpones Second Quarter Investor Conference Call and WebcastGlobeNewswireCHERRY HILL, N.J., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. ("Vyant Bio" or "Company") (NASDAQ:VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company'
4y agoVYNTVyant Bio Announces Investor Conference Call and Webcast for the Second Quarter and First Half of 2022GlobeNewswireCHERRY HILL, N.J., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. ("Vyant Bio" or "Company") (NASDAQ:VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company'
4y agoVYNTVyant Bio Retains Skyline Corporate Communications Group, LLC to Provide Investor Relations ServicesGlobeNewswireCHERRY HILL, N.J., June 01, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. ("Vyant Bio" or "Company") (NASDAQ:VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company'
4y agoVYNTVyant Bio to Present at the H.C. Wainwright Global Investment Hybrid ConferenceGlobeNewswireCherry Hill, N.J., May 19, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. ("Vyant Bio" or "Company") (NASDAQ:VYNT), is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company'
4y agoVYNTVyant Bio Reports First Quarter 2022 Results and Provides Strategic and Business HighlightsGlobeNewswireConference Call and Webcast Today at 4:30 pm ET Scientific and Business Highlights ●Progress in the discovery of small molecule therapeutics to treat neurodevelopmental and neurodegenerative diseases for Rett Syndrome ("Rett"), CDKL5 De
4y agoVYNTVyant Bio Announces Investor Conference Call and Webcast for the First Quarter 2022GlobeNewswireCHERRY HILL, N.J., May 10, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. ("Vyant Bio", "Company") (NASDAQ:VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company's
4y agoVYNTVyant Bio Announces Participation in BioNJ's 12th Annual BioPartnering ConferenceGlobeNewswireCHERRY HILL, N.J., May 05, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. ("Vyant Bio", "Company") (NASDAQ:VYNT), an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders, announced that Ja
4y agoVYNTVyant Bio Reports Fourth Quarter and Year-End 2021 Results and Provides Strategic and Business HighlightsGlobeNewswireHighlights Focused as a pure-play drug discovery and development biotechnology company Primary work on the discovery of small molecule therapeutics to treat neurodevelopmental and neurodegenerative diseases for Rett Syndrome ("Rett"), CDKL5 Deficien
4y agoVYNTVyant Bio and OrganoTherapeutics Announce Strategic Collaboration to Discover Therapeutics to Treat Parkinson's DiseaseGlobeNewswireCherry Hill, N.J. and Esch-sur-Alzette, Luxembourg, March 29, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. ("Vyant Bio", "Company") (NASDAQ:VYNT), an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegene
4y agoVYNTVyant Bio Announces Investor Conference Call and Webcast for the Year-End 2021GlobeNewswireCHERRY HILL, N.J., March 28, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. ("Vyant Bio", "Company") (NASDAQ:VYNT), is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company'
4y agoVYNTVyant Bio Issues Letter to ShareholdersGlobeNewswireCherry Hill, NJ, March 01, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. ("Vyant Bio", the "Company") (Nadsaq:VYNT), is an innovative biotechnology company focused on identifying unique biological targets and novel and repurposed therapeutics. Today Vyant B
4y agoVYNTVyant Bio to Present at the H.C. Wainwright Bioconnect ConferenceGlobeNewswireCherry Hill, N.J., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. ("Vyant Bio", "Company") (NASDAQ:VYNT), an emerging global drug discovery company, is rapidly identifying small and large molecule therapeutics to treat central nervous system (CNS) d
4y agoVYNTVyant Bio to Present at The Benchmark Company Discovery One-on-One Investor ConferenceGlobeNewswireCherry Hill, N.J.,, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. ("Vyant Bio", the "Company") (NASDAQ:VYNT), an emerging global drug discovery company, is rapidly identifying small and large molecule therapeutics to treat central nervous system (
5y agoVYNTVyant Bio Reports Third Quarter 2021 Results and Provides Strategic Business UpdatesGlobeNewswireStrategic Highlights Hired Robert Fremeau, Jr., PhD as Chief Scientific Officer to lead Vyant Bio's R&D programs targeting the identification of novel therapeutics Entered into two new first phase feasibility programs with leading biopharma compan
5y agoVYNTVyant Bio to Present at the Q4 Investor Summit Micro & Small Cap ConferenceGlobeNewswireCherry Hill, N.J., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. ("Vyant Bio", "Company") (NASDAQ:VYNT), an emerging global drug discovery company, is rapidly identifying small and large molecule therapeutics to treat central nervous system (CNS)
5y agoVYNTVyant Bio Announces Investor Conference Call and Webcast for the Third Quarter 2021GlobeNewswireCHERRY HILL, N.J., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. ("Vyant Bio", "Company") (NASDAQ:VYNT), an emerging global drug discovery company, is rapidly identifying small and large molecule therapeutics to treat central nervous system (CNS) a
5y agoAAZZF ABIO ACOGF ACST+81Investor Summit Group Provides Update on Upcoming Q4 Virtual SummitGlobeNewswireNEW YORK, Nov. 05, 2021 (GLOBE NEWSWIRE) -- The Investor Summit Group, widely recognized for its reputation as the host of North America's largest independent investor conferences, will be hosting the upcoming Q4 Virtual Summit on November 16-17. The e
5y agoVYNTVyant Bio Announces Robert T. Fremeau, Jr. Ph.D. as Chief Scientific OfficerGlobeNewswireCherry Hill, N.J., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. ("Vyant Bio", "Company") (NASDAQ:VYNT), an emerging global drug discovery company identifying small and large molecule therapeutics to treat central nervous system (CNS) and oncology-
5y agoVYNTMASORI THERAPEUTICS AND VYANT BIO, INC. ANNOUNCE NEW PARTNERSHIPGlobeNewswireEngagement will combine MASORI's global platforms and commercial experience in Japan to identify partnerships that leverage Vyant Bio's advanced analytics and complex human-derived biology to drive drug discovery Bethesda, MD & Tokyo, Japan and Cher
5y agoVYNTVyant Bio to Present at the H.C. Wainwright 23rd Annual Global ConferenceGlobeNewswireCherry Hill, N.J., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. ("Vyant Bio" or the "Company") (NASDAQ:VYNT), an emerging global drug discovery company, is rapidly identifying small and large molecule therapeutics to treat central nervous system
5y agoVYNTVyant Bio and Cyclica Announce a Strategic Collaboration to Identify Compounds to Treat CDKL5 Deficiency DisorderGlobeNewswireCDKL5 Deficiency Disorder ("CDD") is a severe neurodevelopmental epileptic encephalopathy disorder with no effective treatments or cure Collaboration creates opportunities to identify, validate, and progress new medicines for CDD more rapidly and at a
5y agoVYNTVyant Bio Reports Second Quarter 2021 Results and Provides Strategic Business UpdatesGlobeNewswireStrategic Highlights Received an issued US Patent titled "High Throughput Optical Assay of Human Mixed Cell Population Spheroids" by the United States Patent and Trademark Office (USPTO). The patent
5y agoVYNTVyant Bio to Present at A.G.P.'s Virtual MedTech Summer ConferenceGlobeNewswireCHERRY HILL, N.J., July 27, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. ("Vyant Bio", "Company") (NASDAQ:VYNT), an emerging leader in novel drug discovery, is pleased to announce that Jay Roberts, Chief Executive Officer, will present at A.G.P.'s Virtual
5y agoVYNTVyant Bio Announces Issuance of Key Patent for High-Throughput Optical Assay of Human Mixed Cell Population SpheroidsGlobeNewswireCHERRY HILL, N.J., July 13, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. ("Vyant Bio", the "Company") (NASDAQ:VYNT), an emerging leader in novel drug discovery technologies, announced today that its wholly-owned subsidiary, StemoniX, Inc. ("StemoniX"), wa
5y agoVYNTVyant Bio Inc to Host Earnings CallACCESS NewswireNEW YORK, NY / ACCESSWIRE / May 18, 2021 / Vyant Bio Inc (NASDAQ:VYNT) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 18, 2021 at 8:30 AM Eastern Time. To listen to the event live or access a replay
5y agoVYNTVyant Bio Reports First Quarter 2021 Results and Provides Strategic Business UpdateGlobeNewswireCherry Hill, N.J., May 17, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (the "Company") (NASDAQ:VYNT), is an innovative biotechnology company focused on partnering with pharmaceutical and other biotechnology companies to identify novel and repurposed thera
5y agoVYNTVyant Bio Announces Investor Conference Call and Webcast for First Quarter 2021GlobeNewswireCHERRY HILL, N.J., May 13, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. ("Vyant Bio", "Company") (NASDAQ:VYNT), is focused on integrating human-powered scientific and technology-based systems to de-risk and accelerate the discovery and development of prec
5y agoVYNTVyant Bio to Present at BioNJ's 11th Annual BioPartnering ConferenceGlobeNewswireCHERRY HILL, N.J., May 11, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. ("Vyant Bio", "Company") (NASDAQ:VYNT), is a new force in drug discovery, focused on integrating human-powered scientific and technology-based systems to de-risk and accelerate the dis
5y agoVYNTVyant Bio, Inc., Ordaōs Bio, and Cellaria, Inc. Announce Collaboration to Design and Qualify Biomarker-Specific Small Protein TherapeuticsGlobeNewswireNew collaboration mitigates risk in drug discovery process with artificial intelligence and in vitro "avatar" clinical trials CHERRY HILL, N.J., April 22, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. ("Vyant" or the "Company") (NASDAQ:VYNT), an emergi
5y agoVYNT KYMR LQDA IDRA+1Vyant Bio Announces Newly Appointed Board of DirectorsGlobeNewswireCHERRY HILL, N.J., April 05, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (the “Company”) (Nasdaq: VYNT), is a new force in drug discovery, focused on integrating human-powered scientific and...
5y agoVYNTVyant Bio Announces Investor Webcast to Provide Updates Post Merger between Cancer Genetics and StemoniXGlobeNewswireCHERRY HILL, N.J., April 01, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (the “Company”) (Nasdaq: VYNT), is a new force in drug discovery focused on integrating human-powered scientific and...